A significant response to sunitinib in a patient with anaplastic thyroid carcinoma

Journal of Research in Medical Sciences

Volumn 18, Issue 7, 2013, Pages 622-624

  Grande, Enrique ^a   Capdevila, Jaume ^b   Díez, Juan José ^a   Longo, Federico ^a   Carrato, Alfredo ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Anaplastic thyroid cancer; Angiogenesis; Sunitinib

Indexed keywords

IODINE 131; SUNITINIB; THYROGLOBULIN;

AGED; ARTICLE; ASTHENIA; CANCER RECURRENCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; FOLLOW UP; HUMAN; HUMAN TISSUE; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NECK TUMOR; NEEDLE BIOPSY; NEUTROPENIA; THYROID CARCINOMA; THYROIDECTOMY; TUMOR VOLUME; UPPER GASTROINTESTINAL BLEEDING;

EID: 84882930907     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: Molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009;16:17-44.
3. Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: Pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol) 2010;22:486-97.
4. Gule MK, Chen Y, Sano D, Frederick MJ, Zhou G, Zhao M, et al. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res 2011;17:2281-91.
5. Sosa JA, Elisei R, Jarzab B, Bal CS, Koussis H, Gramza AW, et al. A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial. J Clin Oncol 2011; 29 (15): 5502
6. Savvides P, Nagaiah G, Lavertu PN, Fu P, Wright JJ, Chapman R, et al. Phase II Trial of Sorafenib in Patients with Advanced Anaplastic Carcinoma of the Thyroid. Thyroid 2012;27:15-16
7. Capdevila J, Iglesias L, Halperin I, Segura A, Martinez-Trufero J, Vaz MA, et al. Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer 2012;19(2):209-16
8. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 2008;26:4708-13.
9. Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: An open-label, multicentre, phase II study. Lancet Oncol 2009;10:794-800.
10. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010;16:5260-8.
11. Cohen EE, Needles BM, Cullen KJ, Wong SJ, Wade JL, Ivy SP, et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 2008;26:6025
12. Harvey RD, Kauh JS, Ramalingam SS, Lewis CM, Chen Z, Lonial S, et al. Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer. J Clin Oncol 2010;28:15s.
13. Ravaud A, de la Fouchardiere C, Courbon F, Asselineau J, Klein M, Nicoli-Sire P, et al. Sunitinib in patients with refractory advanced thyroid cancer: The THYSU phase II trial. J Clin Oncol 2008;26:6058
14. De Souza JA, Busaidy N, Zimrin A, Seiwert TY, Villaflor VM, Poluru KB, et al. Phase II trial of sunitinib in medullary thyroid cancer (MTC). J Clin Oncol 2010;28:15s.
15. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
16. Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, et al. Thyroid carcinoma. J Natl Compr Canc Netw 2010;8:1228-74.